COVID-19 vaccine with TLD1433 NML wouldn't have propose to involve testing in a second level-4 lab if our technology didn't have something very unique to their eyes. The fact that the National Research Council was also integrated into the research is extremely telling too as NRC.
That's very securing in regards to our chances to capture the interest of a big pharma in due time.
In July 2022, Theralase® executed a Testing and Technical Services Agreement (“TTSA”) with the National Research Council of Canada (“NRC”) to produce inactivated SARS-CoV-2 virus using Theralase®’s patented PDC and proprietary TLC-3000B medical laser system technology. This inactivated virus will be used to create a vaccine to vaccinate animals to determine the immunogenicity effects of the TLD-1433 SARS-CoV-2 (COVID-19) vaccine and assess its efficacy in protecting the animals from contracting SARS-CoV-2 during SARS-CoV-2 challenge.
Theralase® is currently designing and developing a new proprietary light activation platform; specifically, the TLC-3000B, to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine. The TLC-3000B is expected to be completed for use by PHAC and NRC in 1Q2023.
The above results and completion of the TLC-3000B will lay the groundwork for the next phase of the CRA and TTSA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, at two world class laboratories, when exposed to the virus, which is expected to commence in 1Q2023 and be completed by 1Q2024.
The National Research Council of Canada (NRC) is Canada's largest federal research and development organization.
The NRC partners with Canadian industry to take research impacts from the lab to the marketplace, where people can experience the benefits. This market-driven focus delivers innovation faster, enhances people's lives and addresses some of the world's most pressing problems. We are responsive, creative and uniquely placed to partner with Canadian industry, to invest in strategic R&D programming that will address critical issues for our future.
Each year our scientists, engineers and business experts work closely with thousands of Canadian firms, helping them bring new technologies to market.